The Brain-Wave Trial That Just Raised the Bar for Neuromodulation RCTs
A double-blind tACS trial targeting theta oscillations in methamphetamine patients sets a new design standard regulators will use to...
The CD47 Signal That Oncology Trial Designers Are Misreading
Evorpacept's Phase 2 data in HER2+ gastric cancer reveals a CD47 biomarker selection gap that could reshape how oncology...
The FDA Just Handed Psychedelic Drug Sponsors a Framework. Now the Hard Part Starts.
FDA finalized its psychedelic drug guidance July 14, 2026. COMPASS, Usona, and MAPS now face blinding failures, DEA barriers,...
The Validation Accords: Clinical Trials Are About to Learn What “Validated AI” Actually Means
Nature Medicine's Validation Accords push for a generative AI consensus framework, and expose a regulatory gap that could invalidate...
Early Termination No Longer Means Failure. It Means the Trial Was Working.
Early trial termination once signaled collapse. Now it signals design sophistication, and regulators, sponsors, and CROs need a new...
When a Failed Primary Endpoint Teaches More Than a Win: What CARDIOTTRansform’s Secondary Analysis Reveals About Stratification in Complex Trials
CARDIOTTRansform missed its primary endpoint, but its secondary analysis of eplontersen in ATTR-CM patients on background stabilizers is reshaping...
Psychiatry’s Stratification Crisis: How Biomarkers Are Finally Breaking the DSM’s Grip on Trial Design
Precision psychiatry biomarkers are reshaping CNS trial stratification — here's what the shift from symptom-based DSM criteria to biotype-driven...
AI Antibody Design Just Got Its First Honest Report Card — And the Grade Is Complicated
A blinded 29-org benchmark in Nature Biotechnology tested 511 AI-designed antibodies against experimental data. No single algorithm won. Here's...
The AI Validation Gap: Decision Support Tools Are Outrunning Their Own Evidence
AI clinical trial decision support is a $1.35B market growing at 12.5% annually—but FDA's draft ML guidance and real-world...
The B-Cell Depletion Arms Race in CNS Autoimmune Trials Has a New Front-Runner — And It Rewrites the Regulatory Playbook
Obinutuzumab β's Phase 3 trial shows 93.1% relapse risk reduction in AQP4+ NMOSD, forcing a rethink of how rare...